|
| | Palbociclib-025 Basic information |
| Product Name: | Palbociclib-025 | | Synonyms: | Palbociclib impurity 27/Palbociclib N-Formyl Impurity/4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carbaldehyde;N-Formyl Palbociclib;1-Piperazinecarboxaldehyde, 4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-;Palbociclib E;Palbociclib Impurity 025;4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carbaldehyde? (Palbociclib Impurity） | | CAS: | 2174002-16-3 | | MF: | C25H29N7O3 | | MW: | 475.54 | | EINECS: | | | Product Categories: | | | Mol File: | 2174002-16-3.mol |  |
| | Palbociclib-025 Chemical Properties |
| Boiling point | 765.3±70.0 °C(Predicted) | | density | 1.389±0.06 g/cm3(Predicted) | | solubility | Chloroform (Slightly), DMSO (Slightly) | | form | Solid | | pka | 5.24±0.10(Predicted) | | color | Light Yellow to Very Dark Yellow |
| | Palbociclib-025 Usage And Synthesis |
| Uses | Palbociclib N-Aldehyde is an intermediate in synthesizing Palbociclib N-b-D-Glucuronide Sodium Salt (P139910), a derivative of Palbociclib (P139900) which is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. |
| | Palbociclib-025 Preparation Products And Raw materials |
|
